Trial Profile
Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Antiphospholipid syndrome; Pregnancy complications; Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms IMPACT Study
- 17 Oct 2023 Planned number of patients changed from 50 to 55.
- 17 Oct 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 17 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.